With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up their corporate defences against a potential acquisition. Both Pliant ...
Pliant Therapeutics halted its Phase 2b trial for bexotegrast in IPF, raising concerns about future prospects. Needham downgraded Pliant to Hold from Buy, citing a lack of near-term catalysts and ...
Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to ...
Hosted on MSN1mon
Pliant stock jumps 28% on bexotegrast study updatePliant Therapeutics (NASDAQ:PLRX) stock jumped 28% on Thursday after the company issued an update for a Phase 2b clinical study of bexotegrast in patients with idiopathic pulmonary fibrosis, or ...
Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback